Teva wins FDA OK for crucial migraine drug

order to pay down a very high level of debt stemming from its $39bn acquisition of Allergan’s generics business Actavis in 2015.

Axovant poaches Allergan’s and Teva’s chief medical and science officers

Most recently, Corcoran served as chief medical officer at Allergan and before that he was Actavis’ chief medical officer.

Morning brief: Roche raises outlook for 2018, ASCO abstracts revealed and more

The $64bn sum makes the deal the biggest pharma M&A transaction since Actavis bought Allergan in 2015 for $70.5bn.

Shire warms to Takeda’s latest offer, extending deadline

Analysts suggest however that negative sentiment could still scupper a deal that is by far the largest ever undertaken by the company - and the biggest in pharma since the $70bn

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]